Tenderwize
Zurück zur Suche

Pharmaceutical products

Beschaffer: Bundesministerium für Wirtschaft und Energie (BMWE), Beschafftungsdienstleister: Forschungszentrum Jülich GmbH, Projektträger Jülich (PtJ)·Karlsruhe, Germany·Deadline Oct 31, 2026 · 92 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany-Hamburg: Pharmaceutical products

65/100

Opportunity Score

PromisingMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

65 / 100

Komplexität

40 / 100

Risikofaktoren

The procedure is a voluntary transparency notice, not a public contract under EU directives. Bidders have no procuremen...

No estimated value or guaranteed volume means uncertain revenue. Discounts may be substantial and profitability depends...

No procurement documents available

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Strong opportunity

Wichtige Fakten

  • Supplies contract
  • 3 lots
  • Supply of pharmaceutical products under non-exclusive discount agreements for specified active substances.
  • Agreements aim to bridge the period between patent expiry and exclusive discount contracts.
Vollständige Zusammenfassung anzeigen

Open house procedure for non-exclusive discount agreements (Rabattverträge) under §130a Abs. 8 SGB V for pharmaceutical products. The notice is a voluntary transparency notice, not a public procurement subject to EU directives. The procedure is open to all qualified pharmaceutical entrepreneurs, with contracts awarded to all who meet the requirements. The contract runs from 1 November 2023 to 31 October 2026, with a possible 6-month extension. Ten lots cover various active substances. No estimated value is provided. Submission of participation and contract documents is electronic via the portal, with continuous accession possible during the contract term.

Risiken

The procedure is a voluntary transparency notice, not a public contract under EU directives. Bidders have no procuremen...

No estimated value or guaranteed volume means uncertain revenue. Discounts may be substantial and profitability depends...

No procurement documents available

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Administrative

  • Participation is open to pharmaceutical entrepreneurs (as defined in §4 Abs. 18 AMG) who submit a declaration of suitability and reliability.
  • Bid submission via electronic portal; documents must be submitted with qualified electronic signature or signed original.
  • For timely inclusion of discount pricing in pharmacy software, complete documents must be received by the 3rd of the month prior to the desired start month.

Anforderungen können unvollständig sein.

Auftraggeber

Lose (3)

01

Carbamazepine (RET, N1, N2, N3) - TK, HEK, hkk

Discount agreement for Carbamazepine in specified forms, for participating health insurance funds TK, HEK, and hkk.

Kategorie

Pharmaceutical products

Frist

Deadline Oct 31, 2026

02

Ciclosporin (WKA) - TK, HEK, hkk

Discount agreement for Ciclosporin in specified form, for TK, HEK, hkk.

Kategorie

Pharmaceutical products

Frist

Deadline Oct 31, 2026

03

Levothyroxine sodium (excluding WKA, LSE, TRO, ILO) - TK

Discount agreement for Levothyroxine sodium in specified forms, for TK only.

Kategorie

Pharmaceutical products

Frist

Deadline Oct 31, 2026

Vergabedetails

Veröffentlichungsdatum
19 Sep 2023
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
566780-2023

Ähnliche Ausschreibungen